Zhiwei Zhang
∗ · 2025
Read Zhiwei Zhang by ∗ (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2505-05338.txt.
Introduction
Zhiwei Zhang, Ya Wang, and Dong Xi present a unified way to sharpen trial results for survival outcomes. The catalog title is just the first author's name, so the head title governs here. Their 2025 paper deals with covariate adjustment, which uses baseline data to make trial estimates more precise. Good methods exist for simple outcomes, but survival outcomes lack a widely used one.
Their augmentation approach adds a correction term to a given estimator. The term keeps the meaning, consistency, and normal shape of the result. The best term can be learned by standard or machine learning tools. Tests by computer show large gains in precision. The method ships in an R package called sleete, shown with real data. The authors aim for a tool clinicians can grasp and use.
Catalog record
| CREATOR | ∗ |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2505-05338
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Zhiwei Zhang ∗ Abstract A Unified Approach to Covariate Adjustment for Survival Endpoints in Randomized Clinical Trials Abstract Covariate adjustment aims to improve the statistical efficiency of randomized trials by incorporating information from baseline covariates. Popular methods for covariate adjustment include analysis of covariance for continuous endpoints and standardized logistic regression for binary endpoints. For survival endpoints, while some covariate adjustment methods have been developed for specific effect measures, they are not commonly used in practice for various reasons, including high demands for theoretical and methodological sophistication as well as computational skills. This article describes an augmentation approach to covariate adjustment for survival endpoints that is relatively easy to understand and widely applicable to different effect measures. This approach involves augmenting a given treatment effect estimator in a way that preserves interpretation, consistency, and asymptotic normality. The optimal augmentation term, which minimizes asymptotic variance, can be estimated using various statistical and machine learning methods. Simulation results demonstrate that the augmentation approach can bring substantial gains in statistical efficiency. This approach has been implemented in an R package named sleete , which is described in detail and illustrated with real data. Key words: augmentation; augmented estimator; influence function; machine learning; sample splitting; super learner 1 Introduction Randomized clinical trials are widely considered the gold standard for evaluating the safety and effectiveness of medical treatments. The statistical efficiency of clinical trials can be improved by incorporating information from baseline covariates (i.e., pre-treatment patient characteristics related to clinical outcomes). This usage of baseline covariates, commonly known as covariate adjustment, has received a great deal of attention from practitioners and regulators [ 1 ] . There is a large and growing literature on statistical methods for covariate adjustment in clinical trials [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , e.g.,] . The increased awareness of covariate adjustment has led to increased use of covariate-adjusted methods by pharmaceutical statisticians. For example, it is increasingly common to analyze binary endpoints using standardized logistic regression [ 7 ] . For continuous endpoints, the analysis of covariance method is presumably the most popular method for covariate adjustment. This article is focused on right-censored survival endpoints, for which there seems to be no clear consensus on what is the preferred method for covariate adjustment. It may be tempting to incorporate covariates using a proportional hazards (PH) model; however, this practice changes the estimand from a marginal hazard ratio (HR) into a conditional HR and is susceptible to model mis-specification. The aforementioned literature on covariate adjustment contains several methods developed specifically for survival endpoints, which aim to improve the power of the log-rank test [ 6 , 16 ] and the precision of estimating the HR for treatment in a PH model without baseline covariates [ 3 ] , differences between survival curves [ 10 ] , differences in restricted mean survival time [ 11 , RMST;] , and Mann–Whitney-type effect measures such as the win-lose probability difference [ 14 ] . Possible reasons for their less-than-common use in practice include high demands for theoretical and methodological sophistication as well as computational skills. Some of these methods are developed for specific effect measures and not easily adaptable to others. It would be helpful to practitioners to provide a simple and unified approach that is relatively easy to understand, widely applicable to different effect measures, and readily available in a user-friendly software package. This article describes such a unified approach to covariate adjustment for survival endpoints together with a flexible and easy-to-use implementation. The approach we focus on is a general-purpose augmentation approach in which an initial treatment effect estimator, which typically does not make use of covariate data, is augmented with a term involving treatment assignment and an arbitrary function of covariates [ 2 , 9 , 13 , 14 ] . If the initial estimator is consistent and asymptotically linear, the augmented estimator is also consistent, asymptotically linear and therefore asymptotically normal under mild regularity conditions. The optimal augmentation, which minimizes the asymptotic variance of an augmented estimator, has a simple characterization. To take advantage of this optimality result, one may use a working regression model or a machine learning method to estimate the optimal augmentation and use the estimated augmentation to construct an augmented estimator. The resulting estimator remains consistent and asymptotically normal under fairly general conditions [ 13 , 14 ] . When the estimated augmentation involves machine learning, a sample splitting procedure can be used to maintain asymptotic normality and obtain a cross-validated variance estimate [ 17 , 18 , 19 ] . This approach is implemented in an R package named sleete (super learner for efficient estimation of treatment effects), which provides an option for sample splitting and many choices for estimating the optimal augmentation. As noted earlier, there are many possible effect measures for survival endpoints. The most commonly used one in current practice is probably the HR for treatment in a PH model without baseline covariates. The PH assumption is a strong assumption and should not be taken for granted. Concerns about non-PH have motivated the consideration of alternative effect measures such as differences in survival probability and RMST as well as Mann–Whitney-type effect measures. The augmentation approach described in this article and implemented in the sleete package is flexible enough to accommodate all of these effect measures as well as other, user-defined ones. In other words, we leave the choice of effect measure to the user and strive to improve efficiency in estimating whatever effect measure the user chooses to estimate. When we work with the HR, we regard the PH model as a working model and conceptualize the true estimand as the limit of the maximum partial likelihood estimator [ 20 ] . The sleete package allows the user to define a novel effect measure implicitly by supplying an estimator that is known to be consistent and asymptotically linear. The rest of the article is organized as follows. The augmentation approach is described in Section 2 and evaluated in a simulation study in Section 3 . The sleete package is described in Appendix A and illustrated with real data in Section 4 . The article ends with a discussion in Section 5 . 2 Methodology Consider a randomized clinical trial comparing an experimental treatment ( A=1 ) with a control treatment ( A=0 ) with respect to the time T to a certain failure event, which may be death or a composite of death with other events. Let \boldsymbol{W} be a vector of baseline covariates that may be related to T in one or both treatment groups. Randomization implies that A is independent of \boldsymbol{W} . Due to limited follow-up and possible drop-out, the failure time T may not be fully observed and may be censored by a censoring time C . The observable outcome data consist of X=T\wedge C and \Delta=I(T\leq C) , where \wedge denotes minimum and I(\cdot) is the indicator function. The observed data from an individual subject will be written as \boldsymbol{O}=(\boldsymbol{W},A,X,\Delta) , whose joint distribution is constrained by the known independence between A